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ABSTRACT
Objective: In an international collaborative multicenter pooled analysis, we compared mortality,
functional outcome, intracerebral hemorrhage (ICH) volume, and hematoma expansion (HE)
between non–vitamin K antagonist oral anticoagulation–related ICH (NOAC-ICH) and vitamin K
antagonist–associated ICH (VKA-ICH).
Methods: We compared all-cause mortality within 90 days for NOAC-ICH and VKA-ICH using
a Cox proportional hazards model adjusted for age; sex; baseline Glasgow Coma Scale score,
ICH location, and log volume; intraventricular hemorrhage volume; and intracranial surgery. We
addressed heterogeneity using a shared frailty term. Good functional outcomewas defined as dis-
charge modified Rankin Scale score #2 and investigated in multivariable logistic regression. ICH
volume was measured by ABC/2 or a semiautomated planimetric method. HE was defined as an
ICH volume increase .33% or .6 mL from baseline within 72 hours.
Results: We included 500 patients (97 NOAC-ICH and 403 VKA-ICH). Median baseline ICH volume
was 14.4 mL (interquartile range [IQR] 3.6–38.4) for NOAC-ICH vs 10.6 mL (IQR 4.0–27.9) for VKA-
ICH (p 5 0.78). We did not find any difference between NOAC-ICH and VKA-ICH for all-cause
mortality within 90 days (33% for NOAC-ICH vs 31% for VKA-ICH [p5 0.64]; adjusted Cox hazard
ratio (for NOAC-ICH vs VKA-ICH) 0.93 [95% confidence interval (CI) 0.52–1.64] [p5 0.79]), the rate
of HE (NOAC-ICH n 5 29/48 [40%] vs VKA-ICH n 5 93/140 [34%] [p 5 0.45]), or functional out-
come at hospital discharge (NOAC-ICH vs VKA-ICH odds ratio 0.47; 95%CI 0.18–1.19 [p5 0.11]).
Conclusions: In our international collaborative multicenter pooled analysis, baseline ICH volume,
hematoma expansion, 90-day mortality, and functional outcome were similar following NOAC-
ICH and VKA-ICH. Neurology® 2017;88:1693–1700
GLOSSARY
AF5 atrial fibrillation; CI5 confidence interval;GCS5Glasgow Coma Scale; HE5 hematoma expansion; HR5 hazard ratio;
ICH 5 intracerebral hemorrhage; INR 5 international normalized ratio; IQR 5 interquartile range; IVH 5 intraventricular
hemorrhage;mRS5modified Rankin Scale;NOAC5 non–vitamin K antagonist oral anticoagulant;OAC5 oral anticoagulant;
PCC 5 prothrombin complex concentrate; VKA 5 vitamin K antagonist.
Randomized trials in patients with atrial fibrillation (AF) show that direct (non–vitamin K
antagonist [VKA]) oral anticoagulants (NOACs) have about half the incidence of intracerebral
hemorrhage (ICH) compared to VKA but with a similar efficacy in preventing ischemic
stroke.1 Nevertheless, there is concern that without wide access to specific reversal agents at
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the time of this study, NOAC-associated
ICH (NOAC-ICH) might be larger, with
a higher risk of hematoma expansion (HE)
and worse outcome, than VKA-associated
ICH (VKA-ICH), for which reversal strategies
are established.2–4
There are few data on the clinical and radio-
logic characteristics or the functional outcome
of NOAC-ICH to guide clinicians. A multi-
center prospective study of 61 patients with
NOAC-ICH reported 28% mortality at 90
days, but with no comparison to VKA-ICH.5
Subanalyses of the RE-LY, ARISTOTLE, and
ROCKET-AF trials6–8 suggest similar mortal-
ity for VKA-ICH and NOAC-ICH. However,
a single-center study from Japan (NOAC-
ICH, n 5 5) and a small multicenter study
from the United Kingdom (NOAC-ICH, n5
11) both found that hematoma volume was
smaller in NOAC-ICH compared to VKA-
ICH,9,10 with better or similar functional out-
come at hospital discharge.
We undertook an international, collabora-
tive, multicenter, pooled individual patient
data analysis to systematically describe the
clinical and radiologic characteristics and out-
come of NOAC-ICH in comparison to VKA-
ICH.
METHODS We identified relevant cohorts from an interna-
tional multicenter collaboration.4 To reduce bias and confound-
ing due to secular trends in ICH treatment (including
anticoagulation reversal strategies), we only included VKA-ICH
data after the date of diagnosis of the first included NOAC-ICH
at each center, according to a prespecified protocol. Inclusion
criteria were as follows: ICH while on oral anticoagulation
(NOAC-ICH or VKA-ICH); age over 18 years; for VKA-ICH,
international normalized ratio (INR) on hospital admission
$1.3; for NOAC-ICH, knownNOAC use within 24 hours prior
to ICH clinical symptoms. Exclusion criteria were as follows:
secondary cause for ICH (such as major head trauma in the
previous 24 hours, vascular malformations, tumors, cavernomas,
aneurysms, other known coagulopathy, or hemorrhagic trans-
formation of an infarct); or predominant subarachnoid hemor-
rhage. The primary outcome was mortality by 90 days, adjusted
for potential confounding baseline characteristics. Secondary
outcomes were ICH volume at baseline, proportion of patients
with HE, and functional outcome measured by the modified
Rankin Scale (mRS) at discharge. Some patient data from pre-
viously published studies5,10 were included (NOAC, n 5 33;
VKA, n 5 52).
Clinical and imaging data analysis. We collected clinical,
demographic, and imaging data using a standardized data collec-
tion form. Imaging data included baseline ICH volume measured
from the first available CT scan, using either ABC/2 or semiauto-
mated planimetric measurement, blinded to anticoagulant type
and outcome in all but 3 centers; hematoma location (lobar,
supratentorial deep [basal ganglia and thalamus], brainstem, or
cerebellar); intraventricular hemorrhage (IVH) volume deter-
mined using a semiautomated planimetric method or the modi-
fied Graeb or Hallevi scales4,11,12; and HE, defined as an
increase in volume by .33% or .6 mL from the baseline scan
within 72 hours in patients with their first scan within 6 hours of
symptom onset and without subsequent intracranial surgery
before follow-up imaging, in keeping with a recent collabora-
tion4 and validation.13
Statistical analysis. D.W., D.J.W., A.R.P.-J., and A.M. wrote
a prespecified statistical analysis plan, which was approved by all
participating centers. We compared patient characteristics
between the VKA-ICH and NOAC-ICH groups using appro-
priate analysis for categorical and continuous variables. We
visually inspected the distribution of the continuous variables
using histograms, summarized as medians with interquartile
range (IQR). Differences between the groups were determined
using the Mann-Whitney test (if not normally distributed); cat-
egorical variables between the groups were compared with the x2
test. We log-transformed variables that were not normally dis-
tributed. For IVH volume (where the majority of patients had
0 mL), we modeled using 2 variables: an indicator to model those
with no IVH and a log-transformed variable for those with IVH,
allowing us to generate a hazard ratio (HR) for each milliliter
increase of IVH volume. Univariate Kaplan-Meier estimates were
used to estimate survival probabilities by 90 days for each anti-
coagulant group; the log-rank test was used to compare groups.
Required sample sizes were estimated using a previously re-
ported convenience sample.4 Assuming 90-day mortality (pri-
mary outcome) in the VKA group to be 46%, a study of 50
NOAC and 500 VKA patients has 80% power to identify
a HR of 0.55 (i.e., mortality of 25% vs 46%) with a 2-sided p
value of 0.05. For the secondary outcome of ICH volume, if we
assume VKA-ICH median volume of 18 mL, a study of 50
NOAC and 500 VKA patients has 80% power to identify a dif-
ference of 61% (median 18 vs 11 mL) with a 2-sided p value of
0.05. For the secondary outcome of ICH expansion, we assume
expansion (.6 mL or .33%) to occur in 60% of the VKA
patients (and that only half of VKA and NOAC patients will
have imaging at the required time windows); a study of 25
NOAC and 250 VKA patients has 75% power to identify a dif-
ference between 60% and 33% with a 2-sided p value of 0.05.
Prespecified analyses. For the primary prespecified outcome
analysis, we fitted a Cox proportional hazards model, adjusting
for variables known to affect outcome (age, sex, baseline Glasgow
Coma Scale [GCS] score, log baseline ICH volume, baseline IVH
volume, ICH location, and acute neurosurgery). The assumption
of proportional hazards was assessed by visual inspection of each
log–log plot of survival. Possible heterogeneity in general ICH
management, resources, and ethnicity by site was addressed by
adding a shared frailty term to the model. We performed prespe-
cified subgroup analyses of the primary outcome measure by ICH
location and by individual NOAC agent. A secondary analysis
compared baseline ICH volume between anticoagulants using
a linear regression model with log-transformed ICH volume as
the dependent variable, adjusting for age and ICH location. HE
(yes/no) between anticoagulant groups was investigated with
logistic regression adjusting for age, ICH location, GCS, and
baseline INR.
Post hoc analyses. We explored functional independence at
discharge using the mRS and logistic regression. Discharge
mRS was dichotomized into 0–2 vs 3–6 and adjusted for pre-
morbid mRS, age, and baseline GCS. Shift analysis was the
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prespecified analysis of choice, but our data did not fulfil the
proportional odds assumption. A second post hoc analysis was
undertaken using data only within the first 30 days of follow-up.
Furthermore, we ran individual sensitivity analyses of our primary
outcome adjusting for (in addition to the pre specified variables)
anticoagulation reversal with prothrombin complex concentrate
(PCC) (yes/no), event to presentation time (days), adjustments
for method of volume ascertainment (ABC/2 vs planimetric), and
whether patients came from a consecutive registry. We also
undertook further sensitivity analyses. First, we included a pri-
mary outcome of mortality by 30 days (which might be more
directly related to the effect of the acute ICH); in this analysis, we
included only age, sex, and acute neurosurgery in one model and
age, sex, acute neurosurgery, ICH location, and IVH extension in
another model, excluding baseline characteristics likely to be
confounded by oral anticoagulant type (ICH volume, baseline
GCS, IVH volume). Finally, we undertook a sensitivity analysis
of mortality at 90 days to account for heterogeneity in the ICH
volume measurement method.
Standard protocol approvals, registrations, and patient
consents. This study was approved by the NHSHealth Research
Authority (Research Ethics Committee reference 15/YH/0475).
Responsibility for ensuring compliance with local laws and data
sharing policies was delegated to local principle investigators at
each center, as outlined in the protocol.
RESULTS We retrospectively pooled data from 13
stroke registries from the following countries: United
Kingdom (2 centers and a multicenter prospective
observational study), Finland, the Netherlands, Swit-
zerland, France, Germany, Canada, Australia (2 cen-
ters), Taiwan, and Japan (table 1). We identified 540
patients with oral anticoagulant (OAC)–associated
ICH recruited between April 28, 2012, and August
18, 2015 (registration periods varied by center); 100
participants had NOAC-ICH and 440 had VKA-
ICH. We excluded 40 patients (figure 1); full data-
sets required for the primary analysis were available
for 500 participants (97 with NOAC-ICH and 403
with VKA-ICH) (figure 1). The NOACs used were
apixaban (n 5 13), dabigatran (n 5 13), and rivar-
oxaban (n5 69). Two participants were taking either
rivaroxaban or apixaban. The median follow-up
(accounting for deaths prior to 90 days) was 60
days (IQR 9–196) and varied by center (table 1). The
onset of ICH symptoms to CT scan ranged from
,24 hours (402 patients, 80%) to 11 days (1 patient,
0.2%). ICH volume was rated using the ABC/2
method in 8 centers and a semiautomated planimetric
method in 5 centers. IVH was rated using the mod-
ified Graeb method in 3 centers, the Hallevi score in
6 centers, and a semiautomated planimetric method
in 4 centers. The median INR value within the VKA-
ICH group was 2.7 (IQR 2.2–3.4). The underlying
indication for anticoagulation was known in 415/500
Table 1 Study characteristics by center
Center/registry
Years of
recruitment
Observed deaths
within 90 d, n (%)a
NOAC-
ICH, n
VKA-
ICH, n
ICH volume
rating method
IVH rating
method
Retrospective/prospective;
consecutive/nonconsecutive
Box Hill Hospital, Australia 2014–2015 4 (44) 5 4 ABC/2 Hallevi Retrospective, consecutive
Maastricht University
Medical Center,
Netherlands
2014–2015 10 (71) 2 12 ABC/2 Hallevi Prospective, consecutive
Manchester Academic
Health Sciences Center,
Salford, UK
2013–2015 20 (75) 5 30 Semiplanimetric Semiplanimetric Prospective, consecutive
National Taiwan University
Hospital
2013–2015 7 (39) 6 12 ABC/2 Hallevi Prospective, consecutive
Univ Lille, France 2013–2015 4 (27) 3 12 ABC/2 Hallevi Prospective, consecutive
Helsinki University Hospital,
Finland
2014 5 (28) 2 16 Semiplanimetric Semiplanimetric Retrospective, consecutive
University Hospital Basel,
Switzerland
2012–2015 19 (40) 21 27 ABC/2 Graeb Prospective, consecutive
Ottawa Hospital Research
Institute, Canada
2011–2015 20 (42) 4 44 ABC/2 Hallevi Retrospective, consecutive
Lothian Cerebral
Hemorrhage Registry,
Edinburgh, UK
2014–2015 4 (80) 2 3 ABC/2 Graeb Prospective, nonconsecutive
Royal Melbourne Hospital,
Australia
2014–2015 7 (41) 4 13 Semiplanimetric Semiplanimetric Retrospective, consecutive
Saga University Hospital,
Japan
2013–2015 1 (14) 3 4 ABC/2 Hallevi Prospective, consecutive
Heidelberg University
Hospital, Germany
2012–2014 11 (31) 21 14 Semiplanimetric Graeb Prospective, consecutive (NOAC);
retrospective, consecutive (VKA)
CROMIS-2, United Kingdom 2013–2015 40 (17) 19 212 Semiplanimetric Semiplanimetric Prospective, nonconsecutive
Abbreviations: ICH 5 intracerebral hemorrhage; NOAC 5 non–vitamin K antagonist oral anticoagulant; VKA 5 vitamin K antagonist.
a Not adjusted for censoring.
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patients, as follows: 370 (89%) for AF, 28 (6.7%) for
deep vein thrombosis/pulmonary embolism, 15
(3.6%) for mechanical heart valves, and 2 (0.5%) for
cardiomyopathy. All but 1 of these patients was on
a VKA.
The patient characteristics for NOAC-ICH and
VKA-ICH are shown in table 2; those with
NOAC-ICH more often had cerebellar ICH and
worse premorbid mRS compared with VKA-ICH,
but were otherwise similar. OAC reversal informa-
tion was available in 450 patients (365 VKA-ICH
and 85 NOAC-ICH); of these, 286/365 (78%)
participants with VKA-ICH received 3 or 4 factor
PCC, compared to 35/85 (41%) of participants
with NOAC-ICH (p # 0.001). Twenty-four pa-
tients with VKA-ICH (6%) and 7 patients with
NOAC-ICH (7%) were treated with acute
neurosurgery.
Primary outcome. There were 161 deaths (a crude
mortality rate of 32%). After adjusting for censoring,
all-cause mortality was 31% at 90 days. Ninety-day
mortality was 33% (95% confidence interval [CI]
24–44) for NOAC-ICH vs 31% (95% CI 27–37) for
VKA-ICH (p 5 0.64). Age, admission GCS, and
ICH volume were associated with 90-day mortality in
univariable analysis (table 3). After adjusting for
baseline variables (age, sex, baseline GCS, log baseline
ICH volume, baseline IVH volume, ICH location,
and acute neurosurgery) and addressing heterogeneity
by site (using a shared frailty term), there was no
difference in survival between NOAC-ICH and
VKA-ICH (HR 0.93; 95% CI 0.52–1.64; p 5 0.79)
(figure 2 and table 3). In post hoc analyses, the pri-
mary result was unchanged as follows: PCC treatment
(HR 0.99; 0.57–1.72), ICH onset to presentation
time (HR 0.81; 95% CI 0.49–1.35), ICH volume
measurement method (HR 0.80; 95% CI 0.48–
1.35), and consecutive registry source (HR 0.84;
95% CI 0.50–1.38). There was no between-group
difference in 30-day mortality (HR NOAC-ICH vs
VKA-ICH 0.83; 95% CI 0.47–1.48; p 5 0.53) or
Figure 1 Flowchart of study design and patient selection
GCS 5 Glasgow Coma Scale; ICH 5 intracerebral hemorrhage; INR 5 international normalized ratio; NOAC 5 non–vitamin K antagonist oral anticoagulant;
OAC 5 oral anticoagulation; VKA 5 vitamin K antagonist anticoagulant.
Table 2 Characteristics of participants with non–vitamin K antagonist oral
anticoagulant (NOAC)–associated intracerebral hemorrhage (ICH) and
vitamin K antagonist (VKA)–associated ICH
Variable NOAC-ICH (n 5 97) VKA-ICH (n 5 403)
Age, y, median (IQR) 80 (74–85) 80 (72–85)
Male sex, n (%) 53 (55) 196 (49)
ICH location
Lobar area 38 (39) 158 (39)
Supratentorial deep areas 40 (41) 198 (49)
Cerebellum 13 (13) 26 (6)
Brainstem 6 (6) 21 (5)
Glasgow Coma Scale, median (IQR) 14 (12–15) 15 (13–15)
Acute neurosurgery, n (%) 7 (7) 24 (6)
IVH extension, n (%) 42 (43) 146 (36)
Premorbid mRS, median (IQR)a 1 (0–3) 0 (0–2)
Early palliation, n (%) 11 (13) 28 (7)
Anticoagulation for atrial fibrillation, n (%) 85/86 (99) 267/332 (80)
Abbreviations: IQR 5 interquartile range; IVH 5 intraventricular hemorrhage; mRS 5 mod-
ified Rankin Scale.
Values are n (%) or median (IQR).
a Available in 431 patients.
1696 Neurology 88 May 2, 2017
60-day mortality (HR NOAC-ICH vs VKA-ICH
0.75; 95% CI 0.44–1.30; p 5 0.308).
For the outcome of mortality by 30 days
(including age, sex, acute neurosurgery in model
1 and age, sex, acute neurosurgery, ICH location,
and IVH extension as covariates in model 2) the
main result was unchanged (HR for NOAC-ICH
vs VKA-ICH 0.88 [95% CI 0.53–1.45] for model
1 and 0.94 [95% CI 0.55–1.59] [p 5 0.813] for
model 2) (supplemental data at Neurology.org). In
sensitivity analyses for the outcome of mortality by
90 days including log ICH volume assessed by
different methods (ABC/3, planimetry), the main
result for NOAC-ICH vs VKA-ICH also remained
unchanged (see supplemental data).
Secondary outcomes. Median baseline VKA-ICH
volume was 10.6 mL (IQR 4.0–27.9), compared
to 14.4 mL (IQR 3.6–38.4) for NOAC-ICH (p 5
0.78). There was no statistical difference in log-
transformed ICH volumes in multivariable linear
regression (coefficient 0.06; 95% CI 20.28 to
0.41, p 5 0.72). Data regarding HE were available
in 188 patients (140 [35%] VKA-ICH and 48
[49%] NOAC-ICH), and did not vary by antico-
agulant type (NOAC-ICH 29/48 40% vs VKA-
ICH 93/140 34%, p 5 0.45); there was no
between-group difference in HE after multivari-
able logistic regression adjusting for age, ICH
location, baseline INR, and GCS (OR 1.38; 95%
CI 0.46–4.18; p 5 0.57).
Participants with VKA-ICH were more likely to be
functionally independent at discharge than those with
NOAC-ICH in univariable analysis (23% vs 10%,
respectively, p, 0.001), but not in multivariable logis-
tic regression after adjusting for premorbid mRS, age,
IVH extension, and baseline GCS (NOAC vs VKA-
ICH: OR 0.47; 95% CI 0.18–1.19; p5 0.11). Back-
wards stepwise regression suggested that a baseline
Table 3 Cox proportional hazards models: univariable and multivariable analyses for the primary outcome of
90-day mortality
Variables Units
Univariable model Multivariable model
HR (95% CI) p Value HR (95% CI) p Value
Sex Female 1.00 (reference) 1.00 (reference)
Male 1.08 (0.77–1.51) 0.65 0.92 (0.68–1.32) 0.654
Age Per year 1.04 (1 .02–1.06) 0.001 1.04 (1.01–1.06) 0.002
GCS Per point 0.81 (0.78–0.85) 0.001 0.85 (0.80–0.89) 0.001
ICH volume Per (log) mL 1.58 (1.38–1.82) 0.001 1.38 (1.17–1.64) 0.001
IVH volume Per (log) mL 1.525 (1.37–1.70) 0.001 1.18 (0.98–1.44) 0.081
ICH location Lobar area 1.00 (reference) 1 (reference)
Supratentorial deep areas 0.94 (0.67–1.32) 0.74 1.26 (0.83–1.90) 0.277
Cerebellum 0.73 (0.36–1.49) 0.39 1.31 (0.59–2.93) 0.514
Brainstem 0.94 (0.42–2.14) 0.89 3.36 (1.30–8.70) 0.012
Neurosurgery vs no neurosurgery 0.84 (0.41–1.71) 0.63 0.45 (0.20–1.00) 0.051
Anticoagulant type VKA 1.00 (reference) 1 (reference)
NOAC 1.10 (0.73–1.67) 0.65 0.93 (0.52–1.64) 0.792
Abbreviations: CI 5 confidence interval; GCS 5 Glasgow Coma Scale; HR 5 hazard ratio; ICH 5 intracerebral hemorrhage;
IVH 5 intraventricular hemorrhage; NOAC 5 non–vitamin K antagonist oral anticoagulant; VKA 5 vitamin K antagonist.
Figure 2 Survival curve comparing non–vitamin K oral antagonist anticoagulant
(NOAC)–associated intracerebral hemorrhage (ICH) and vitamin K
antagonist anticoagulant (VKA)–associated ICH 90-day mortality
Adjusted for age; sex; baseline Glasgow Coma Scale score, ICH location, and log volume;
intraventricular hemorrhage volume; and intracranial surgery.
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difference in premorbid mRS between NOAC-ICH
and VKA-ICH accounts for the difference between
the univariable and multivariable analysis results.
DISCUSSION Our multicenter, international indi-
vidual patient pooled analysis of 500 participants with
OAC-ICH found that 90-day mortality for NOAC-
ICH is similar to that for VKA-ICH. Functional
outcome, ICH volume, and HE were also similar
between the NOAC-ICH and VKA-ICH groups. We
found no statistically significant differences between
individual NOAC-ICH 90-day mortality rates,
although the numbers of participants taking each
individual OAC were limited. We found no signifi-
cant difference between NOAC-ICH and VKA-ICH
in a post hoc analysis of 30-day mortality.
Although previous small studies suggested that
hematoma volume was smaller for NOAC-ICH com-
pared to VKA-ICH, with better or similar functional
outcome at hospital discharge, these included only 5
and 11 participants with NOAC-ICH, respec-
tively,9,10 and were not statistically powered to detect
differences in ICH volume or outcome. Furthermore,
hospital discharge mRS might not reflect longer-term
outcome and is prone to confounding by premorbid
mRS. We included 90-day mortality, which more
accurately reflects longer term outcome and is less
prone to confounding. Although previous animal
models suggest that hematoma expansion does not
occur with therapeutic doses of NOACs (rivaroxaban
and dabigatran),14,15 supported by small human case
series (n 5 5 and 6),9,16 a recent multicenter registry
(n 5 61) described hematoma expansion with
NOACs,5 consistent with our study. The real-world
mortality we report for NOAC-ICH and VKA-ICH
is in keeping with findings from the RE-LY (mortality
for VKA-ICH 36% vs dabigatran-ICH 35% [150
mg] and 41% [110 mg]),6,17 ROCKET-AF (mortality
for VKA-ICH 50% vs rivaroxaban-ICH 48%),7 and
ARISTOTLE (mortality for VKA-ICH 42.3% vs
apixaban-ICH 45.3%)8 randomized trials.
Our study has important strengths. We include
a large cohort of patients with both NOAC-ICH
and VKA-ICH. The use of detailed individual patient
clinical and radiologic data allowed us to describe
baseline characteristics and key clinically relevant out-
comes beyond the acute phase of hospital admission,
and to adjust for important potential confounding
factors. Because we included prospectively collected
clinical data from Europe, North America, East Asia,
and Australasia, our findings are likely to be more
generalizable to a real-life OAC-ICH population in
broad range of health care settings than any of the
previous studies. We reduced bias from secular treat-
ment trends by only including NOAC-ICH and
VKA-ICH recruited during the same time period,
and from the same patient population, from each par-
ticipating center. Our primary outcome of 90-day
mortality is unlikely to be substantially confounded
by premorbid functional status.
We also acknowledge limitations: functional out-
come at 90 days would have been a preferable second-
ary outcome to discharge mRS, as it is less
confounded by length of stay, but these data were
not available. We do not know how widely NOAC
adoption was within each source population, which
could lead to confounding by indication. Although
we compared and adjusted for baseline characteristics
between NOAC-ICH and VKA-ICH patients, there
might be unmeasured confounding factors, including
clinician judgement used in choosing between a VKA
or a NOAC, alcohol intake, blood pressure variability,
or comorbidities such as renal disease, which we could
not fully account for. These may be of some concern
especially as NOACs are contraindicated in some set-
tings. Two registries did not enroll every patient with
OAC-ICH; exclusion of severe ICHmight have caused
ascertainment bias, but in our post hoc sensitivity anal-
ysis this did not affect 90-day mortality.
Our reported 90-day mortality (31%) is lower
than some previous series of anticoagulant-related
ICH (range 46%–68%)18 although similar to that
reported in a recent German multicenter registry
study (28%).5 Follow-up duration and ICHmortality
varied between centers; although we used a shared
frailty model, this cannot fully account for all
between-center heterogeneity. We acknowledge some
measurement heterogeneity due to 2 different meth-
ods for rating ICH volumes, but ensured that each
center rated both VKA-ICH and NOAC-ICH using
the same method. Furthermore, adjusting for this
heterogeneity in sensitivity analysis did not alter the
primary result. Finally, hematoma expansion data
were only available in 188/500 patients, and were
more often available in NOAC-ICH, so might not
be generalizable to the entire cohort.
Our finding that ICH volume, HE, and func-
tional outcomes were similar for NOAC-ICH and
VKA-ICH might have implications for clinical prac-
tice. NOACs have a lower risk of ICH than VKA
for ischemic stroke prevention in populations with
AF.1 Reversal agents for NOAC-related hemorrhage,
including NOAC-ICH, have been developed, and are
likely to become more widely available (although
these agents are not yet established as clinically effec-
tive in patients with NOAC-ICH).19–22 Our study
therefore does not support previous concerns that
NOAC-ICH might have poorer outcome than
VKA-ICH because of a lack of available specific rever-
sal agents.2,3 Nevertheless, further randomized data
for detailed NOAC-ICH functional outcome and
radiologic profiles compared to VKA-ICH are
1698 Neurology 88 May 2, 2017
needed. Furthermore, little is known about the risk of
NOAC-ICH or its functional outcome in patients at
high risk of ICH, e.g., those with previous ICH or
with bleeding-prone arteriopathies.23 As specific
NOAC-ICH reversal agents become available, studies
of how these affect clinical and radiologic outcomes
are needed. Other treatment options for NOAC-
ICH, including hemostatic agents24 and acute blood
pressure management,25 also need to be investigated,
ideally in randomized controlled trials.
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